#123 – Ravneesh Sachdev

This KGI Industry Talk features Ravneesh Sachdev, the Vice President and Head of Business Development at Sage Therapeutics, based in Cambridge, MA. Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, including Zulresso™, the first FDA-approved drug specifically for postpartum depression. Ravneesh evaluates and transacts on partnerships in order to inorganically grow Sage’s business.

Over the past 15+ years of his business development career, Ravneesh has contributed to, as well as led, the execution of more than 20 partnerships during his tenure at several other companies, namely Pfizer, Onyx Pharmaceuticals (now part of Amgen), UCB Pharma, Acorda Therapeutics, and Bioverativ (now part of Sanofi).

Ravneesh earned his bachelor’s degree in Molecular Neuroscience from Claremont McKenna College, his Master of Business and Science degree from KGI, and his MBA in Healthcare Leadership from Yale University School of Management.